Ivosidenib for previously treated advanced cholangiocarcinoma

Cholangiocarcinoma is a rare type of cancer that affects the bile ducts. Different subtypes of cholangiocarcinoma are classified by the location at which they develop in the biliary tract. Genetic changes (mutations) to the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) plays a central role in development of cholangiocarcinoma by contributing to the growth of abnormal cancerous cells. Currently there are limited treatment options for advanced or metastatic (where the cancerous cells have spread to other areas of the body) IDH1 gene-mutated cholangiocarcinoma and the prognosis for these patients remains poor.